Comparison of Risks of Thromboembolism of Drospirenone-Containing and Nondrospirenone -Containing Combined Oral Contraceptive Use: A Meta-Analysis  

作　　者：Wan-Lin Zhang Zhe Dong Jun-Yan Zhang Min-Zhi Lyu Wei Zhang Jian-Lei Huang Xin Yang 

机构地区：[1]Reproductive Medical Center,Department of Obstetrics and Gynecology,Tangdu Hospital,the Airforce Military Medical University,Xi’an 710038,China [2]Department of Obstetrics and Gynecology,Peking University International Hospital,Beijing 102206,China [3]Bothwin Clinical Study Consultant,Redmond,WA 98053,USA [4]Department of Biostatistics,Zhongshan Hospital,Fudan University,Shanghai 200032,China [5]Center of Evidence-Based Medicine,Fudan University,Shanghai 200433,China [6]Department of Biostatistics,School of Public Health,Fudan University,Shanghai 200433,China [7]Department of Obstetrics and Gynecology,Peking University People’s Hospital,Beijing 100044,China

出　　处：《Reproductive and Developmental Medicine》2021年第3期154-160,共7页生殖与发育医学（英文版）

摘　　要：This study aimed to estimate the risk of venous thromboembolism(VTE),arterial thromboembolism(ATE),and other side effects following the use of drospirenone(DRSP)-containing combined oral contraceptives(COCs).When compared with non-DRSP-containing COCs,DRSP-containing COCs decreased the risk of VTE by 15%in the overall study population,although this was not statistically significant(adjusted hazard ratio/risk ratio[95%confidence interval]0.85[0.69,1.04]).DRSP-containing COCs also showed significant benefits in terms of ATE risk.The body mass index of the subjects significantly decreased by 0.64 kg/m^(2) after taking the DRSP-containing COCs for 6 months.We concluded that DRSP-containing COCs were safe for use and could be broadly recommended.

关 键 词：Arterial Thromboembolism Combined Oral Contraceptives DROSPIRENONE Venous Thromboembolism 

分 类 号：R169.41[医药卫生—公共卫生与预防医学]